Therapeutic potential of dipeptidyl peptidase-IV inhibitors in patients with diabetes mellitus.

Abstract

Dipeptidyl peptidase-IV (DPP-IV) inhibitors are a new class of oral antidiabetic agents for the treatment of patients with type 2 diabetes. Inhibition of the enzyme DPP-IV results in increased activity of glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic peptide (GIP), the incretin hormones. Through the action of GLP-1 and GIP, DPP-IV inhibitors improve preprandial and postprandial glucose by enhancing insulin secretion and reducing postprandial concentrations of glucagon. This review examines the background, current evidence, and future therapeutic potential of this novel class of drug.

• Authors: Kevin B Moore, Christopher D Saudek
• Journal: American journal of therapeutics (Am J Ther) 2008 Sep-Oct Vol. 15 Issue 5 Pg. 484-91 ISSN: 1536-3686 [Electronic] United States
• PMID: 18806525 (Publication Type: Journal Article, Review)

Chemical References

• Blood Glucose
• Dipeptidyl-Peptidase IV Inhibitors
• Glycated Hemoglobin A
• Hypoglycemic Agents
• Incretins
• Gastric Inhibitory Polypeptide
• Glucagon-Like Peptide 1

Topics

• Blood Glucose (analysis)
• Clinical Trials as Topic
• Diabetes Mellitus, Type 2 (drug therapy)
• Dipeptidyl-Peptidase IV Inhibitors (pharmacology, therapeutic use)
• Gastric Inhibitory Polypeptide (metabolism)
• Glucagon-Like Peptide 1 (metabolism)
• Glycated Hemoglobin (analysis)
• Humans
• Hypoglycemic Agents (pharmacology, therapeutic use)
• Incretins (metabolism)